News for Alphamab Oncology (9966.HK)

SUZHOU, China, June 3, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors.

SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)), has completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS) as evaluated by an Independent Data Monitoring Committee (IDMC), with both statistical significance and clinical relevance.

SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which is held in Chicago, USA, from April 25 to 30, 2025.

SUZHOU, China, March 26, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

SUZHOU, China, March 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer (PROC), primary peritoneal cancer, or fallopian tube cancer, not restricted to HER2 expression levels.

SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer.

SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-301). The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer. This marks the third Phase III clinical study initiated for JSKN003, following the trials in HER2 low-expressing breast cancer and platinum-resistant ovarian cancer.

SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (study number: JSKN003-306). The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This study has previously been included in the 'Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs'.

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology Immuno-Oncology Congress 2024 (ESMO IO Congress 2024).

SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, were presented for the first time as a poster in the Late-Breaking Abstract (LBA) session at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in 2024 (SITC 2024).

SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound Docetaxel HB1801 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer.

SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ('Alphamab'), a wholly-owned subsidiary of Alphamab Oncology ('the Company'), entered into a licensing agreement (the 'Licensing Agreement') on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology Co., Ltd. ('JMT-Bio'), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (stock code: 1093.HK).

SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona, Spain. Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.

SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 in patients with platinum-resistant ovarian cancer and patients with advanced HER2-positive (IHC 3+) solid tumors, will be presented as posters at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona, Spain.

Simcere Pharmaceutical holds a 9% stake in 3D Medicines, making it the firm’s second-biggest shareholder. It chose not to cash out any of its holdings when the stock was surging.